DiaMedica Therapeutics Inc. (DMAC) News
Follow DiaMedica Therapeutics Inc. (DMAC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it w
NEWS | Sep 30, 2026, 12:30 PM UTC
L
DiaMedica management to participate in four September investor conferences
DiaMedica Therapeutics management will participate in four upcoming investment bank conferences in September, the company said.
EQUITY | Sep 02, 2026, 12:30 PM UTC
L
DMAC Starts Phase 2 Trial
DMAC DiaMedica Therapeutics announces first patients dosed in Phase 2 trial of DM199 for the treatment of fetal growth restriction
EQUITY | Jun 23, 2026, 12:32 PM UTC